In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
This is a prospective observation study to generate patient-derived organoids from patients' samples to assess treatment response and to correlate with patients' treatment outcomes and to collect preliminary data on the ability of PDOs to predict patients' treatment response and whether their radiosensitivity and chemosensitivity can be correlated with their survival outcome.
Study Type
OBSERVATIONAL
Enrollment
60
Guys Hospital
London, United Kingdom
RECRUITINGSuccessful Organoids
To assess the percentage of successful generated organoids from tissues in head and neck cancer patients
Time frame: 1 Year
Sensitivity
To assess the sensitivity of radiotherapy, platinum (cisplatin and/or carboplatin) chemotherapy or cetuximab or their combination in PDOs
Time frame: 1 Year
Treatment Outcome
To correlate the treatment sensitivities of PDOs with the treatment outcome of patients
Time frame: 1 Year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.